Edison Investment Research - mutares AG (A2NB65) QuickView: European restructuring specialist

Report

Edison Investment Research

QuickView: European restructuring specialist

mutares is a restructuring specialist in the European market, acquiring companies that are undergoing special situations, providing extensive operational support and disposing at a profit once turnaround is complete. Having entered a very active M&A phase, the group has successfully completed several acquisition and disposal deals in 2015. With a successful capital increase on 8 October providing further funds to invest in both new opportunities and bolt-ons, following the opening of a new Paris office in March 2015, we expect to see M&A activity continuing.

09/11/2015 2 EN

Underlying

mutares AG

Mutares AG. Mutares AG is a Germany-based holding company focused on acquiring companies in special situations, such as owner or management succession and re-funding. It is active in the Automotive, Construction and Infrastructure, Consumer Goods and Logistics, Engineering and Technology, and Wood and Paper sectors. Its Automotive portfolio includes Elastomer Solutions, a manufacturer of rubber moldings, and STS Group, a producer of acoustic and thermal insulation. In the Construction and Infrastructure segment it manages manufacturing companies La Meusienne (stainless steel tubes), EUPEC (pipeline coatings) and BSL Pipes and Fittings (pipeline components). The Consumer Goods portfolio includes KLANN, a manufacturer of tinplate packaging. The Engineering and Technology portfolio includes Balcke-Duerr, a manufacturer of power plant components. Manufacturing companies Cenpa (core board), Zanders (specialty paper) and Norsilk (wood paneling and floor coverings) comprise the Wood and Paper segment.

See profile

DE000A0SMSH2 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

SmartInsider

Mutares SE & Co. KGaA: 1 director

A director at Mutares SE & Co. KGaA sold 40,000 shares at 27.585EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Free Trial

October 27, 2023 October 27, 2023 1 EN

Edison Investment Research

Mutares - Focus on engineering & technology

Mutares (MUX) continues to align its portfolio with the companyâ€™s core strategy and competencies. This includes the good progress in the turnaround of Balcke-DÃ¼rr, which clearly contributed to the improvement in adjusted group EBITDA to â‚¬4.5m (FY17: â‚¬-27.9m). Moreover, MUX further developed its engineering & technology segment through a new platform investment and several add-on acquisitions to existing platforms. Finally, it has deconsolidated unpromising entities from non-core segments which contributed negative results in FY18. MUX expects to acquire three additional companies and ex...

April 30, 2019 April 30, 2019 5 EN

Edison Investment Research

Mutares - New platform investments on board

After reporting c â‚¬9m of adjusted EBITDA in H118, Mutares expects FY18 earnings to reach â‚¬20â€“30m. This should be assisted by successful turnarounds and organic growth of portfolio entities, beneficial M&A activity and the deconsolidation of Zanders and Artmadis, which are currently being liquidated. Management expects one or two additional transactions (either acquisitions or divestments) to be initiated and completed in the remainder of 2018, on top of the Knorr-Bremse deal which is already in progress. At the current share price of â‚¬9.54, Mutares is trading at a 40.5% discount to las...

October 10, 2018 October 10, 2018 5 EN

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

17h / 34m 17h / 34m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

17h / 46m 17h / 46m 1 EN

Martyn King

Martyn King

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

18h / 4m 18h / 4m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: European restructuring specialist

Mutares SE & Co. KGaA: 1 director

Mutares - Focus on engineering & technology

Mutares - New platform investments on board

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Foxtons Group - FY24 underpinned by market share gains

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe